EcoDrugPlus

Neuromedin-K Receptor-Like

Ensembl ID : ENSSFOG00015025707
Gene Symbol: LOC108924307
3 Cross references
129 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSSFOG00015009677
Gene Symbol: LOC108942234
2 Cross references
140 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSSFOG00015015182
Gene Symbol: NPY2R
3 Cross references
245 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSSFOG00015024149
Gene Symbol: NPY2R
3 Cross references
245 Possible Orthologues:

Neuropeptide Y Receptor Y4-2

Ensembl ID : ENSSFOG00015017878
Gene Symbol: NPY4R2
1 Cross references
116 Possible Orthologues:

Neuropeptide Y Receptor Y5

Ensembl ID : ENSSFOG00015014190
Gene Symbol: NPY5R
1 Cross references
135 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSSFOG00015017357
Gene Symbol: NTSR1
3 Cross references
203 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSSFOG00015009438
Gene Symbol: NTRK2
3 Cross references
209 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSSFOG00015023611
Gene Symbol: NTRK3
1 Cross references
203 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSSFOG00015019029
Gene Symbol: NTRK3
1 Cross references
203 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSSFOG00015024172
Gene Symbol: NTRK1
1 Cross references
197 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSSFOG00015009061
Gene Symbol: NTRK1
1 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).